Avid Bioservices Inc (CDMO)

[sunstar]

Peregrine definitely has a strategy to seek FDA approvals in cancer indications with a high unmet need. This has been discussed by the company, and I believe Dr. Garnick is centrally focused on this approach.

The third leading cause of cancer related deaths in the world is in liver cancer (HCC). Peregrine is now running a 56 patient phase I/II trial in advanced liver cancer (HCC) using bavituximab and sorafenib. Here is the IST trial:

http://clinicaltrials.gov/ct2/show/NCT01264705?term=bavituximab&rank=10

Here is a poster that shows the pre-clinical data around bavi and sorafenib in HCC.

http://www.peregrineinc.com/images/stories/pdfs/aacr_hcc.pdf

Here is another interesting website that has some informative mapping of cancer indications showing high unmet need and other categories of treatment and occurrence.

http://www.bionest.com/publications/OncologyPipelines.pdf

sunstar